Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2013 | 12-2012 | 12-2011 | 12-2010 | 12-2009 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 3,267,000 | 7,646,000 | 12,283,000 | 10,977,000 | 10,807,000 |
| Depreciation Amortization | 4,583,000 | 2,518,000 | 2,550,000 | 2,741,000 | 2,087,000 |
| Accounts receivable | -383,000 | 755,000 | -1,108,000 | 10,000 | N/A |
| Accounts payable and accrued liabilities | 414,000 | -1,311,000 | 467,000 | -16,000 | N/A |
| Other Working Capital | 166,000 | -706,000 | -897,000 | 82,000 | 1,329,000 |
| Other Operating Activity | -647,000 | -1,954,000 | -5,474,000 | -3,114,000 | -2,484,000 |
| Operating Cash Flow | $7,400,000 | $6,948,000 | $7,821,000 | $10,680,000 | $11,739,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 130,000 | 3,619,000 | -2,743,000 | -125,000 | N/A |
| PPE Investments | -673,000 | -473,000 | -737,000 | -708,000 | -824,000 |
| Net Acquisitions | -1,158,000 | -1,187,000 | 1,772,000 | -348,000 | 0 |
| Purchase Of Investment | -91,000 | -46,000 | -11,000 | -34,000 | N/A |
| Sale Of Investment | 38,000 | 43,000 | N/A | 5,000 | N/A |
| Purchase Sale Intangibles | -1,281,000 | -3,947,000 | -458,000 | -1,180,000 | N/A |
| Other Investing Activity | -1,135,000 | -3,815,000 | -303,000 | -1,016,000 | -1,652,000 |
| Investing Cash Flow | $-2,889,000 | $-1,859,000 | $-2,022,000 | $-2,226,000 | $-2,476,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -5,000 | 687,000 | 46,000 | -8,000 | N/A |
| Debt Issued | N/A | 1,980,000 | N/A | N/A | N/A |
| Debt Repayment | N/A | -1,750,000 | N/A | -1,741,000 | N/A |
| Common Stock Issued | 482,000 | 429,000 | 409,000 | 494,000 | N/A |
| Common Stock Repurchased | N/A | -2,635,000 | -6,015,000 | -2,604,000 | N/A |
| Dividend Paid | -3,461,000 | -3,665,000 | -3,764,000 | -3,361,000 | -2,977,000 |
| Other Financing Activity | -63,000 | 31,000 | 3,000 | -114,000 | -652,000 |
| Financing Cash Flow | $-3,047,000 | $-4,923,000 | $-9,321,000 | $-7,334,000 | $-3,629,000 |
| Exchange Rate Effect | -65,000 | -4,000 | -25,000 | 33,000 | 71,000 |
| Beginning Cash Position | 7,596,000 | 7,434,000 | 10,981,000 | 9,828,000 | 4,123,000 |
| End Cash Position | 8,995,000 | 7,596,000 | 7,434,000 | 10,981,000 | 9,828,000 |
| Net Cash Flow | $1,399,000 | $162,000 | $-3,547,000 | $1,153,000 | $5,705,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 7,400,000 | 6,948,000 | 7,821,000 | 10,680,000 | 11,739,000 |
| Capital Expenditure | -742,000 | -672,000 | -839,000 | -791,000 | N/A |
| Free Cash Flow | 6,658,000 | 6,276,000 | 6,982,000 | 9,889,000 | 11,739,000 |